A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY(TM) (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD

Trial Profile

A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY(TM) (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Clonidine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Shionogi
  • Most Recent Events

    • 21 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Planned End Date changed from 1 Jul 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top